DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NALMEFENE HYDROCHLORIDE

Clinical Trials for Nalmefene Hydrochloride

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00000437	Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)	Completed	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 4	The purpose of this study is to determine the effectiveness of naltrexone (Revia) in reducing drinking and smoking in patients with both nicotine and alcohol dependence. Individuals will be randomly assigned to a 12-week trial of a fixed daily dose of either naltrexone (Revia) and nicotine replacement patch or placebos. All individuals will receive weekly coping skills and smoking-cessation behavioral therapy. Followup interviews will be conducted 3 and 6 months after treatment to determine smoking and drinking status and persistence of any dependence symptoms.
NCT00000437	Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)	Completed	The Scripps Research Institute	Phase 4	The purpose of this study is to determine the effectiveness of naltrexone (Revia) in reducing drinking and smoking in patients with both nicotine and alcohol dependence. Individuals will be randomly assigned to a 12-week trial of a fixed daily dose of either naltrexone (Revia) and nicotine replacement patch or placebos. All individuals will receive weekly coping skills and smoking-cessation behavioral therapy. Followup interviews will be conducted 3 and 6 months after treatment to determine smoking and drinking status and persistence of any dependence symptoms.
NCT00000450	Naltrexone Maintenance Treatment of Alcoholism	Completed	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 4	The purpose of this study is to determine the long-term effectiveness of naltrexone treatment in alcohol-dependent patients who respond to short-term treatment. Those who respond to short-term treatment will be randomized to a 1-year, double-blind, placebo-controlled maintenance phase with a 6-month posttreatment followup.
NCT00000450	Naltrexone Maintenance Treatment of Alcoholism	Completed	The Scripps Research Institute	Phase 4	The purpose of this study is to determine the long-term effectiveness of naltrexone treatment in alcohol-dependent patients who respond to short-term treatment. Those who respond to short-term treatment will be randomized to a 1-year, double-blind, placebo-controlled maintenance phase with a 6-month posttreatment followup.
NCT00132119	Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling	Completed	Somaxon Pharmaceuticals	Phase 2/Phase 3	The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.
NCT00202696	Nalmefene Smoking Cessation Study	Completed	Somaxon Pharmaceuticals	Phase 2	To determine if nalmefene is safe and effective in smoking cessation.
NCT00811720	Efficacy of Nalmefene in Patients With Alcohol Dependence	Completed	H. Lundbeck A/S	Phase 3	The purpose of the study is to evaluate the efficacy, safety and tolerability of nalmefene in the treatment of alcohol dependence.
Trial ID	Title	Status	Sponsor	Phase	Summary